HONEST LIMITS

Where organ chips fall short

Chips model a piece of an organ, not a whole body. Most lack immune cells, nerves and hormones. PDMS can soak up drugs, results vary between labs, and chips are slower and costlier than plates of cells.

A good chip answers one question well and says what it cannot do.

REGULATION

What the rules now allow

2022 The U.S. FDA Modernization Act 2.0 removed the requirement that new drugs be tested in animals before human trials

What it means Methods such as cell-based assays, organ chips and computer models can be used where appropriate

2025 The FDA announced a plan to reduce animal testing, starting with antibody drugs, and to encourage new approach methods

The law now allows alternatives, but they still have to prove they work.

PROVING IT

Validation

✅

To be trusted, a chip must give the right answer for drugs whose effects in people are already known. In one 2022 study, a liver chip flagged most of a set of drugs known to injure the human liver while not flagging safe ones. More studies like this, across labs and organs, are what regulators want.

Trust is earned drug by drug, with known answers.

BEYOND BIOLOGY

Microfluidics everywhere

🌍

❄️

Chip cooling

Liquid flowing through microchannels can cool hot processors

⚗️

Flow chemistry

Small reactors make chemicals and drugs more safely and consistently

🔋

Energy

Microfluidic fuel cells and batteries use laminar streams

The same physics serves medicine, electronics, chemistry and energy.

WHAT'S NEXT

Where the field is heading

Expect more human and patient-derived cells, chips moulded in plastic in standard formats that robots can handle, built-in sensors, and AI that reads the data. Microfluidics engineers, cell biologists and data scientists will build it together.

The future: more human biology, made more like a product.

UNIT 20 STUDY COMPLETE

🚀

Ready for the Fab Challenge?

You've finished the course: from the physics of tiny channels to organs on chips, their limits and their future.